Bluefin Capital Management’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-30,200
Closed -$5.59K 241
2023
Q4
$5.59K Sell
30,200
-6,300
-17% -$530K ﹤0.01% 194
2023
Q3
$1.9K Sell
36,500
-11,100
-23% -$1.24M ﹤0.01% 174
2023
Q2
$2.38K Buy
+47,600
New +$6.35M ﹤0.01% 157
2023
Q1
Sell
-39,400
Closed -$6.3K 374
2022
Q4
$6.3K Buy
+39,400
New +$6.44M ﹤0.01% 363

Other funds holding MRNA

Bluefin Capital Management's MRNA Position: Q3 2020 in Review

Bluefin Capital Management sold out of Moderna (MRNA) in Q3 2020, closing a stake of 3,508 shares — an estimated $245K sold.

Bluefin Capital Management first reported a position in MRNA in Q2 2020 and held it in 1 quarter. The position peaked at $225K in Q2 2020. 548 funds tracked by Wall St. Rank hold MRNA as of Q3 2020.

  • Bluefin Capital Management reported no remaining Moderna position as of Q3 2020 after selling out during the quarter.
  • Bluefin Capital Management sold 3,508 Moderna shares in Q3 2020, an estimated $245K.
  • Bluefin Capital Management first reported a position in Moderna in Q2 2020 and held it in 1 quarter.
  • Bluefin Capital Management's Moderna position peaked at $225K in Q2 2020.
  • 548 funds tracked by Wall St. Rank held Moderna as of Q3 2020.

Based on Bluefin Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.